Chemosensory receptor ligand-based therapies
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
1. A method of treating diabetes in a subject in need thereof, comprising administering to said subject a composition comprising metformin or a salt thereof, wherein said composition is adapted for delivery to enteroendocrine cells distal of the duodenum to minimize metformin plasma absorption in said subject.
2. The method according to claim 1 , wherein said diabetes is type II diabetes.
3. The method according to claim 1 , wherein said metformin salt is metformin hydrochloride.
4. The method according to claim 1 , wherein said composition is adapted to release a therapeutically effective amount of metformin downstream of the jejunum, to the intestine.
5. The method according to claim 4 , wherein said composition is adapted to release a therapeutically effective amount of metformin to the ileum and/or lower intestine.
6. The method according to claim 1 , wherein said composition releases metformin at an onset of about pH 5.5, about pH 6.0, about pH 6.5, about pH 7.0, or a combination thereof following administration to said subject.
7. The method according to claim 6 , wherein said composition releases metformin at an onset of about pH 5.5 following administration to said subject.
8. The method according to claim 6 , wherein said composition releases metformin at an onset of about pH 6.0 following administration to said subject.
9. The method according to claim 6 , wherein said composition releases metformin at an onset of about pH 6.5 following administration to a subject.
10. The method according to claim 1 , wherein said composition releases metformin at an onset of about pH 7.0 following administration to said subject.
11. The method according to claim 1 , wherein said therapeutically effective amount of metformin or salt thereof is about 1 mg to about 2000 mg.
12. The method according to claim 1 , wherein said therapeutically effective amount of metformin or salt thereof is about 10 mg to about 1500 mg.
13. The method according to claim 11 , wherein said therapeutically effective amount of metformin or salt thereof is about 2000 mg.
14. The method according to claim 12 , wherein said therapeutically effective amount of metformin or salt thereof is about 1500 mg.
15. The method according to claim 1 or 2 , wherein said composition comprising metformin or a salt thereof has a lower average bioavailability as compared to an immediate release metformin formulation having an equivalent amount of metformin.
16. The method according to claim 1 , wherein said composition further comprises a second antidiabetic agent.
17. The method according to claim 16 , wherein said second antidiabetic agent is selected from the group consisting of thiazolidinediones, sulfonyureas, meglitinides, alpha-glucosidase inhibitors, DPP-IV inhibitors, incretin mimetics, and SGLT inhibitors.
18. The method according to claim 1 , wherein said composition further comprises an antiobesity agent.
19. The method according to claim 18 , wherein said antiobesity agent is selected from the group consisting of phentermine, fenfluramine, sibutramine, rimonabant, topiramate, zonisamide, bupropion, naltrexone, lorcaserin, and orlistat, and combinations thereof.
20. The method according to claim 1 , wherein said composition further comprises a chemosensory receptor ligand selected from the group consisting of a sweet receptor ligand, a bitter receptor ligand, an umami receptor ligand, a fat receptor ligand, a sour receptor ligand, and a bile acid receptor ligand.
21. The method according to claim 1 , wherein said composition comprises an enteric coating.
22. The method according to claim 1 , wherein said composition is formulated with a timed release system.
23. The method according to any one of claims 16 to 19 , wherein said antiobesity agent or said antidiabetic agent is co-formulated with said composition and administered simultaneously in a combined formulation.
24. The method according to claim 23 , wherein said combined formulation is provided in the form of a delayed release component coupled with an immediate release component in a unitary dosage form.